论文部分内容阅读
本文通过前瞻性多中心协作研究,对卡铂开展了临床Ⅰ～Ⅱ期试用。全组共320例,Ⅰ期10例,Ⅱ期310例。认为卡铂的合适剂量是300～400mg/m~2,静脉滴注,4周一次。限制剂量提高的因素为骨髓抑制。卡铂单用或联合其他药物对肺癌、卵巢癌、食管癌、头颈部鳞癌均有较好的疗效。与同期127例以顺铂为主的化疗方案对比,消化道反应相对较轻,血液学及肝肾功能毒性相近。结论认为卡铂是一有希望的新药,在肿瘤的综合治疗中占有一定地位。
This article through the prospective multi-center collaborative research, carried out clinical trial I ~ II trial of carboplatin. There were 320 cases in the whole group, 10 cases in phase I and 310 cases in phase II. It is considered that the appropriate dose of carboplatin is 300-400 mg/m~2, intravenous drip, once every 4 weeks. The limiting dose increase factor is myelosuppression. Carboplatin alone or in combination with other drugs has a good effect on lung cancer, ovarian cancer, esophageal cancer, head and neck squamous cell carcinoma. Compared with 127 chemotherapy regimens based on cisplatin during the same period, the digestive tract reaction was relatively mild, and hematology and liver and kidney function were similar in toxicity. Conclusions Carboplatin is a promising new drug and occupies a certain position in the comprehensive treatment of tumors.